|Mr. Daniel E. Greenleaf||CEO, Pres & Director||749.52k||N/A||1965|
|Mr. Stephen M. Deitsch||Sr. VP, CFO & Treasurer||375k||N/A||1973|
|Ms. Harriet Booker||Sr. VP & COO||415k||N/A||1966|
|Ms. Kathryn M. Stalmack||Sr. VP, Gen. Counsel & Sec.||338k||N/A||N/A|
|Mr. John McMahon||VP, Controller & Chief Accounting Officer||N/A||N/A||1965|
BioScrip, Inc. provides infusion and home care management solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care. It also offers home nursing products and services to patients suffering from chronic and acute medical conditions. The company provides its services at patient's home, outpatient clinics, nursing facilities, physician's offices, and ambulatory infusion centers. BioScrip, Inc. offers its solutions through sales and marketing representatives, and payor relationships. The company was incorporated in 1996 and is based in Denver, Colorado.
BioScrip, Inc.’s ISS Governance QualityScore as of April 1, 2019 is 6. The pillar scores are Audit: 10; Board: 2; Shareholder Rights: 7; Compensation: 6.